<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03320265</url>
  </required_header>
  <id_info>
    <org_study_id>ATH3G10-005</org_study_id>
    <nct_id>NCT03320265</nct_id>
  </id_info>
  <brief_title>Phosphorylcholine PC-mAb Effects in Subjects With Elevated Lipoprotein a</brief_title>
  <official_title>Double-blind, Randomised, Placebo-controlled, Multicentre, Phase IIa Study to Investigate the Effect of PC-mAb on Arterial Inflammation in Subjects With Elevated Lipoprotein a</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Athera Biotechnologies AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Athera Biotechnologies AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammation and abnormal amount of lipids in the blood are key factors for the development
      and progression of atherosclerosis (thickening of the artery wall) and cardiovascular
      disease. Lipoprotein (a) is a pro-inflammatory plasma lipoprotein that is believed to be a
      risk factor for cardiovascular diseases. Vascular inflammation generates a range of effects,
      including endothelial dysfunction and migration of white blood cells into the vessel wall,
      which results in increased risk of cardiovascular events.

      This study is designed to assess the effects of multiple monthly intravenous infusions with
      the fully human antibody called PC-mAb, in subjects with elevated lipoprotein (a).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Monocyte function</measure>
    <time_frame>From baseline (Day 1) to visit 11 (Day 85)</time_frame>
    <description>Change in transendothelial migration (TEM) in monocytes isolated from treated subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial inflammation</measure>
    <time_frame>From baseline (Day 1) to visit 11 (Day 85)</time_frame>
    <description>Change in tissue to background ratio (TBRmax) in common carotid arteries by fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>From baseline (Day 1) to visit 11 (Day 85)</time_frame>
    <description>Change in pulse wave velocity (PWV) (m/sec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)/serious AEs (SAEs)</measure>
    <time_frame>From baseline (Day 1) to visit 11 (Day 85)</time_frame>
    <description>Incidence of AEs/SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs, height</measure>
    <time_frame>At screening (Day -63 to -1)</time_frame>
    <description>in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs, body weight</measure>
    <time_frame>At screening (Day -63 to -1), Day 1, Day 28, Day 56, Day 84 and end of study (Day 143)</time_frame>
    <description>in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs, blood pressure</measure>
    <time_frame>At screening (Day -63 to -1), Day 1, Day 28, Day 56, Day 84 and end of study (Day 143)</time_frame>
    <description>in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs, hear rate</measure>
    <time_frame>At screening (Day -63 to -1), Day 1, Day 28, Day 56, Day 84 and end of study (Day 143)</time_frame>
    <description>in bpm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs, body temperature</measure>
    <time_frame>At screening (Day -63 to -1), Day 1, Day 28, Day 56, Day 84 and end of study (Day 143)</time_frame>
    <description>in °C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination including review of all organ systems</measure>
    <time_frame>At screening (Day -63 to -1), Day 1, Day 28, Day 56, Day 84 and end of study (Day 143)</time_frame>
    <description>Any abnormalities will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (ECG), PR (PQ)</measure>
    <time_frame>At screening (Day -63 to -1), Day 1, Day 28, Day 56, Day 84 and end of study (Day 143)</time_frame>
    <description>12-lead ECG; PR (PQ) interval (in msec) will be measured and reported descriptively; any abnormalities will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG, QRS</measure>
    <time_frame>At screening (Day -63 to -1), Day 1, Day 28, Day 56, Day 84 and end of study (Day 143)</time_frame>
    <description>12-lead ECG; QRS interval (in msec) will be measured and reported descriptively; any abnormalities will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG, QT</measure>
    <time_frame>At screening (Day -63 to -1), Day 1, Day 28, Day 56, Day 84 and end of study (Day 143)</time_frame>
    <description>12-lead ECG; QT interval (in msec) will be measured and reported descriptively; any abnormalities will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG, QTcF</measure>
    <time_frame>At screening (Day -63 to -1), Day 1, Day 28, Day 56, Day 84 and end of study (Day 143)</time_frame>
    <description>12-lead ECG; QTcF interval (in msec) will be measured and reported descriptively; any abnormalities will be recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Arterial Inflammation</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>PC-mAb</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phosphorylcholine human monoclonal antibody, i.v. infusions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to PC-mAb, i.v. infusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PC-mAb</intervention_name>
    <description>Monthly treatment for 3 months (4 administrations)</description>
    <arm_group_label>PC-mAb</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Monthly treatment for 3 months (4 administrations)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major inclusion criterion:

          -  Lp(a) above 50 mg/dL at screening

        Major exclusion criteria:

          -  Medical history of myocardial infarction (MI) or stroke within 12 months of screening

          -  Ongoing or paroxysmal atrial fibrillation

          -  Clinically overt heart failure

          -  Hypertension defined as ≥180/100 mmHg

          -  Diabetes mellitus

          -  Systemic autoimmune diseases requiring treatment

          -  Cancer, excluding basal cell carcinoma, within the last five years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric SG Stroes, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carina Schmidt</last_name>
    <phone>+46 (0)761 938 190</phone>
    <email>c.schmidt@athera.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Vascular Medicine, Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric SG Stroes, MD, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CTC Clinical Trial Consultants AB</name>
      <address>
        <city>Uppsala</city>
        <zip>75237</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Folke Sjöberg, MD, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2017</study_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phosphorylcholine human monoclonal antibody</keyword>
  <keyword>Lipoprotein a</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Arteritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

